WP
AVBP icon

Woodline Partners’s ArriVent BioPharma AVBP Stock Holding History

Woodline Partners’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.13M Hold
147,639
– – 0.02% 685
2026
Q1 		$3.41M Buy
147,639
+253
+0.2% +$5.71K 0.01% 726
2025
Q4 		$2.97M Sell
147,386
-149,530
-50% -$3.11M 0.01% 718
2025
Q3 		$5.48M Buy
296,916
+150,000
+102% +$2.95M 0.03% 544
2025
Q2 		$3.2M Buy
146,916
+543
+0.4% +$11.3K 0.02% 642
2025
Q1 		$2.71M Buy
146,373
+576
+0.4% +$14.1K 0.02% 620
2024
Q4 		$3.88M Buy
145,797
+24,853
+21% +$714K 0.03% 535
2024
Q3 		$2.84M Buy
120,944
+20,944
+21% +$475K 0.02% 444
2024
Q2 		$1.85M Hold
100,000
– – 0.02% 423
2024
Q1 		$1.79M Buy
+100,000
New +$2.02M 0.02% 430

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Woodline Partners's AVBP Position: Q2 2026 in Review

Woodline Partners held its ArriVent BioPharma (AVBP) position steady in Q2 2026 at 147,639 shares worth $5.13M. The position accounts for 0.02% of the portfolio, ranked #685.

Woodline Partners first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. The position peaked at $5.48M in Q3 2025. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Woodline Partners held 147,639 shares of ArriVent BioPharma worth $5.13M as of Q2 2026.
  • Woodline Partners left its ArriVent BioPharma share count unchanged in Q2 2026.
  • ArriVent BioPharma made up 0.02% of Woodline Partners's portfolio in Q2 2026, its #685 holding.
  • Woodline Partners first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • Woodline Partners's ArriVent BioPharma position peaked at $5.48M in Q3 2025.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.